Barclays PLC Ab Cellera Biologics Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Barclays PLC holds 22,293 shares of ABCL stock, worth $65,764. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,293

Previous 22,293 -0.0%

Holding current value

$65,764

Previous $58,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$2.39 - $3.49 $3,501 - $5,112	1,465 Added 7.03%	22,293 $58,000
Q2 2024 Aug 14, 2024	SELL	$2.73 - $4.73 $413,676 - $716,736	-151,530 Reduced 87.92%	20,828 $62,000
Q1 2024 May 15, 2024	BUY	$4.29 - $5.97 $221,797 - $308,654	51,701 Added 42.85%	172,358 $780,000
Q4 2023 Feb 15, 2024	BUY	$3.91 - $5.93 $389,713 - $591,049	99,671 Added 474.94%	120,657 $689,000
Q3 2023 Nov 07, 2023	SELL	$4.6 - $7.95 $2.32 Million - $4.01 Million	-504,978 Reduced 96.01%	20,986 $97,000
Q2 2023 Aug 03, 2023	BUY	$5.66 - $7.59 $30,807 - $41,312	5,443 Added 1.05%	525,964 $3.4 Million
Q1 2023 May 04, 2023	BUY	$7.31 - $11.18 $1.49 Million - $2.28 Million	203,493 Added 64.19%	520,521 $3.93 Million
Q4 2022 Feb 13, 2023	BUY	$9.48 - $14.52 $764,372 - $1.17 Million	80,630 Added 34.11%	317,028 $3.21 Million
Q3 2022 Nov 03, 2022	SELL	$9.2 - $13.68 $44,436 - $66,074	-4,830 Reduced 2.0%	236,398 $2.34 Million
Q2 2022 Aug 12, 2022	SELL	$5.72 - $10.65 $39,136 - $72,867	-6,842 Reduced 2.76%	241,228 $2.57 Million
Q1 2022 May 16, 2022	BUY	$7.46 - $14.14 $1.85 Million - $3.51 Million	248,070 New	248,070 $2.42 Million

Others Institutions Holding ABCL

# of Institutions

154

Shares Held

109M

Call Options Held

153K

Put Options Held

194K

View Full List

About AbCellera Biologics Inc.

Ticker ABCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 285,139,008
Market Cap $841M
Description
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...

More about ABCL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account